A Phase I/IIa Trial to Evaluate Safety and Efficacy of CLDN6 CAR-T and CARVac Based In Vivo Expansion to Improve Treatment of Patients with CLDN6-Positive Advanced Solid Tumors

Time: 2:30 pm
day: Day Two


  • Preliminary Ph1 data on FIH trial with CLDN6-CART +/- CARVac incl. safety, PK/PD and efficacy data
  • Focus on combination with CARVac for in vivo expansion of CLDN6-CART
  • Update on exploratory biomarker program